Impilo acquires VaccinDirekt – the leading Nordic retail vaccination provider
VaccinDirekt is the leading Nordic vaccination provider in a winning channel enjoying strong underlying growth, primarily driven by increased public awareness for vaccines, the enhanced focus on preventive healthcare, and a steadily growing pipeline of new vaccines. The Company is well positioned to extend its leadership, leveraging its unparalleled quality, know-how, and customer focus, coupled with a large physical footprint in central locations, offering superior convenience and availability to its growing base of more than 1.4 million registered customers.
Read moreNews
Scantox Group acquires Gentronix
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”), well recognized for its high-quality genetic toxicology services and strong scientific engagement.
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.